Bli medlem
Bli medlem

Du är här

2016-02-03

Immune Pharmaceuticals: Immune Pharmaceuticals Names John Neczesny to its Board of Directors

IMMUNE PHARMACEUTICALS NAMES JOHN NECZESNY TO ITS BOARD OF DIRECTORS

Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage
biopharmaceutical company, announced today that it has appointed John
Neczesny to its Board of Directors. Mr. Neczesny will be a member both of
the Audit Committee and of the Compensation Committee. This appointment
will place Immune in compliance with the NASDAQ listing rules relating to a
majority of independent directors and the composition of the audit
committee and compensation committees.

"We are delighted to have John join our Board of Directors" said Dr. Daniel
Teper, CEO of Immune. "John's experience will bring expertise and
discipline to future financial and corporate development transactions as
Immune unlocks the value of its pipeline."

Mr. Neczesny brings over 27 years of investment banking and corporate
experience to this role. Mr. Neczesny has been a Managing Director at
Oberon Securities, LLC, a boutique investment bank, since 2012, where he
advises on and executes M&A and financing transactions principally for
healthcare companies. Previously, he was Vice President, Corporate
Development at Par Pharmaceutical Companies from 2009 to 2011. From 1998 to
2008, Mr. Neczesny was an investment banker at Bear Stearns & Co. Inc. in
the Healthcare group, where he rose to Managing Director and was involved
in numerous M&A and capital markets transactions for pharmaceutical,
biotechnology and medical technology companies. Mr. Neczesny earned an MBA
in Finance from New York University Stern School of Business and a Bachelor
of Science degree in Chemistry from the University of Delaware.

Mr. Neczesny stated, "I am pleased to be joining the Immune board at this
point in the Company's evolution. With the continuing clinical progress of
bertilimumab and the advancement of its immuno-oncology pipeline, Immune
has several programs that offer interesting potential for development and
partnership. I look forward to contributing my experience to help the
Company execute its strategy."

NEW YORK, Feb. 2, 2016

For further information:
Danielle Shapira, Manager, Strategic Planning,
IMMUNE Pharmaceuticals, Inc., 646.440.9327,
danielle.shapira@immunepharma.com

The following documents can be retrieved from beQuoted
Immune Pharmaceuticals Pressrelease 2016-02-03.pdf

About Immune Pharmaceuticals:
Immune Pharmaceuticals (NASDAQ: IMNP) applies a personalized approach to
treating and developing novel, highly targeted antibody therapeutics to
improve the lives of patients with inflammatory diseases and cancer.
Immune's lead product candidate, bertilimumab, is in phase II clinical
development for moderate-to-severe ulcerative colitis as well as for
bullous pemphigoid, an orphan autoimmune dermatological condition. Other
indications being considered for development include atopic dermatitis,
Crohn's disease, severe asthma and NASH (an inflammatory liver disease).
Immune recently expanded its portfolio in immuno-dermatology with topical
nano-formulated cyclosporine-A for the treatment of psoriasis and atopic
dermatitis. Immune's oncology pipeline includes bispecific antibodies,
nanotherapeutics, including NanomAbs®, and several mid-to-late stage small
molecules. Immune's noncore pipeline includes AmiKet™, a late clinical
stage drug candidate for the treatment of neuropathic pain. For more
information, visit Immune's website at
, the content of which is not a part
of this press release.

Forward-Looking Statements
This news release and any oral statements made with respect to the
information contained in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. You are urged to consider statements that include the words
"may," "will," "would," "could," "should," "believes," "estimates,"
"projects," "potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal" or the negative of those words
or other comparable words to be uncertain and forward-looking. Such
forward-looking statements include statements that express plans,
anticipation, intent, contingency, goals, targets, future development and
are otherwise not statements of historical fact. These statements are based
on our current expectations and are subject to risks and uncertainties that
could cause actual results or developments to be materially different from
historical results or from any future results expressed or implied by such
forward-looking statements. Factors that may cause actual results or
developments to differ materially include, but not limited to: the risks
associated with the adequacy of our existing cash resources and our ability
to continue as a going concern; the risks associated with our ability to
continue to meet our obligations under our existing debt agreements; the
risk that clinical trials for bertilimumab or AmiKet will not be
successful; the risk that bertilimumab, AmiKet or compounds arising from
our NanomAbs program will not receive regulatory approval or achieve
significant commercial success; the risk that we will not be able to find a
partner to help conduct the Phase III trials for AmiKet on attractive
terms, on a timely basis or at all; the risk that our other product
candidates that appeared promising in early research and clinical trials do
not demonstrate safety and/or efficacy in larger-scale or later-stage
clinical trials; the risk that we will not obtain approval to market any of
our product candidates; the risks associated with dependence upon key
personnel; the risks associated with reliance on collaborative partners and
others for further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product development,
clinical trials and regulatory approval process; our history of operating
losses since our inception; the highly competitive nature of our business;
risks associated with litigation; and risks associated with our ability to
protect our intellectual property. These factors and other material risks
are more fully discussed in our periodic reports, including our reports on
Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and
Exchange Commission. You are urged to carefully review and consider the
disclosures found in our filings, which are available at
or at . You are
cautioned not to place undue reliance on any forward-looking statements,
any of which could turn out to be wrong due to inaccurate assumptions,
unknown risks or uncertainties or other risk factors. We expressly disclaim
any obligation to publicly update any forward looking statements contained
herein, whether as a result of new information, future events or otherwise,
except as required by law.

SOURCE Immune Pharmaceuticals, Inc.

Författare BEQ

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.